TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: As shown in Figure3A, we treated K562 cells, which are a Ph+ and Tp53‐deleted CML cell line, with different concentrations of PMIBcr/Abl‐R6 and Bcr/Abl‐R6.